Next Article in Journal
The Sex Differences in Uveal Melanoma: Potential Roles of EIF1AX, Immune Response and Redox Regulation
Previous Article in Journal
Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse
Article

Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study

1
CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
2
Max Rady Faculty of Health Sciences, College of Nursing, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
3
Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
4
Department of Epidemiology and Cancer Registry, CancerCare Manitoba Research Institute, Winnipeg, MB R3E 0V9, Canada
5
Section of Hematology/Oncology, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0W2, Canada
*
Author to whom correspondence should be addressed.
Received: 25 June 2021 / Revised: 20 July 2021 / Accepted: 20 July 2021 / Published: 22 July 2021
Patients with advanced pancreatic cancer (APC) experience many disease-related symptoms. ESAS-r measures the severity of 9 symptom domains and has been validated for use in the ambulatory oncology setting. We aimed to describe symptom burden at baseline for patients with APC treated with modern chemotherapy (CT), and to determine whether symptom burden at baseline is prognostic. Patients diagnosed with APC between 2012–2016, treated with ≥1 cycle of CT, who completed ≥1 ESAS-r were identified. Descriptive statistics were used to report symptom burden and common moderate-to-severe symptoms. A joint model was used to describe the trajectory of ESAS-r during follow-up while controlling for death. Multivariable Cox regression was used to identify independent predictors of death. Of 123 patients identified, the median age was 65 and 61% had metastatic disease. The median baseline ESAS-r total symptom distress score (TSDS) was 24. A total of 86% of patients had at least one symptom score of ≥4 at baseline, with the most common being: fatigue, nausea, anxiety, and shortness of breath. Median overall survival was 10.2 months. Baseline TSDS was not predictive for worse survival in the era of modern CT. Patients with APC have a high burden of cancer-associated symptoms and a high prevalence of moderate-to-severe symptoms. Early intervention has the potential to improve quality of life in this group of patients and should be investigated. View Full-Text
Keywords: symptom burden; pancreatic cancer; patient-reported outcomes; ESAS; prognosis symptom burden; pancreatic cancer; patient-reported outcomes; ESAS; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Lelond, S.; Ward, J.; Lambert, P.J.; Kim, C.A. Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study. Curr. Oncol. 2021, 28, 2789-2800. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28040244

AMA Style

Lelond S, Ward J, Lambert PJ, Kim CA. Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study. Current Oncology. 2021; 28(4):2789-2800. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28040244

Chicago/Turabian Style

Lelond, Stephanie, Julie Ward, Pascal J. Lambert, and Christina A. Kim 2021. "Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study" Current Oncology 28, no. 4: 2789-2800. https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol28040244

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop